Can two old drugs together save young livers?

NCT ID NCT06091345

Completed Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving both midodrine (a blood-pressure drug) and albumin (a protein infusion) to children with cirrhosis and fluid buildup (ascites) could prevent serious complications like kidney injury, low sodium, and confusion. Sixty-one children were split into two groups: one got midodrine plus albumin, the other got midodrine alone. The goal was to see if the combo worked better than midodrine alone at reducing these life-threatening problems.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: midodrine and albumin
What this could lead to: If successful, this combination could help prevent serious complications like kidney injury and improve survival in children with advanced liver disease.
What could go wrong: This is a small, single-center trial with only 61 children. The results may not apply to all patients, and the combination may not provide a clear benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DECOMPENSATED CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER CIRRHOSIS

Contacts and locations

Locations

Institute of Liver & Biliary Sciences (ILBS)

New Delhi, National Capital Territory of Delhi, 110 070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.